University of California

Sankyo Company, Limited

Jerrold M Olefsky

Kenneth R Chien

Dean Lockwood

Rebecca Norris

Tammy Antonucci

Lisa Lesniewski

Tahir S Pillay

Yun Sok Lee

Mohammad Pashmforoush

Isao Usui

Da Young Oh

Takeshi Imamura

Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes, obesity, atherosclerosis, stroke, myocardial infarction, and other cardiovascular diseases, by modulating FKN/CX3CR1 expression levels or activities, and its downstream signaling pathways in a subject in need or at risk.

Target for diagnosis and treatment of diabetes and cardiovascular diseases

The present invention provides methods of treating a &#x3b2;-arrestin2 mediated and/or GPR120 mediated response in a subject. The &#x3b2;-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound predicted to bind a &#x3b2;-arrestin2 molecule and/or GPR120, wherein the compound selectively activates a &#x3b2;-arrestin2-dependent signaling pathway of GPR120.

Methods of treating inflammatory conditions

Provided are methods of treating insulin resistance or type II diabetes. Disrupting CAP in the macrophage can alter the inflammatory response associated with impaired insulin action and ultimately result in improved insulin action in target tissues. One aspect of the invention involves administering a CAP antagonist to a patient afflicted with insulin resistance or type II diabetes in an amount sufficient to improve insulin action in target tissues.

Diabetes treatment methods and drug targets therefor

The invention herein provides a mode of treating metabolic syndrome, which includes Type 2 diabetes mellitus and insulin resistance in human and other subjects by identifying and administering an insulin sensitizing compound which modulates GRK2 function in the insulin signaling pathway. The invention also provides polynucleotides, polypeptides, vectors, cells, tissues and organisms useful in the identification and treatment of metabolic syndrome. A number of desirable insulin sensitizing aspects are achieved by various embodiments of the present invention.

Methods of identifying compounds for producing insulin sensitization

Methods and compositions are provided for the treatment of insulin-resistance through the inhibition of protein kinase C-mediated phosphorylation of the amino acid residue Ser of the insulin receptor. Methods for testing candidate compounds suitable for inhibition of serine-phosphorylation by protein kinase C are also provided.

Protein kinase C antagonist related to insulin receptor

A screening method for identifying compositions which affect the binding of protein tyrosine phosphatase 1B (PTP1B) to phosphorylated insulin receptor is provided. This method measures a composition's ability to inhibit binding of PTP1B to the .beta.-subunit of the insulin receptor rather than phosphatase activity in general. Also provided are specific phosphopeptides which affect the binding of protein tyrosine phosphatase 1B (PTP1B) to phosphorylated insulin receptor.

Method for treatment of insulin resistance

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations exhibiting insulin resistent non-impaired glucose tolerance (IRNIGT) in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed.

Use of thiazolidinedione derivatives and related antihyperglycemic

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose intolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed.

Growing community of inventors

Solana Beach, CA, United States of America

Jerrold M Olefsky